Noopept – ethyl ester of N-phenylacetyl-L-prolylglycine – a new Russian nootropic dipeptide, created in the Scientific Research Institute of Pharmacology of V.V. Zakusov. As a non-peptide prototype of this preparation, piracetam was chosen, and as a peptide, vasopressin.
It was taken into account that dipeptides (in comparison with more complex peptides) are distinguished by biological stability, and in enterocytes, there is a specific ATP-dependent system for the transport of dipeptides. Several studies have shown high bioavailability of the drug in brain tissue after oral administration.
Noopept has a good safety and tolerability profile, and because of that you can buy noopept as a dietary supplement in many places. The development of Noopept was carried out within the framework of the existing idea that some regulatory neuropeptides exert a significant influence on the mechanisms of memory formation and learning.
Noopept has a complex mechanism of action. The nootropic effect of the drug is mediated by one of its active metabolites (cycloprolylglycine) is similar in structure to an endogenous cyclic dipeptide with anti-amnesic activity. Noopept has a nootropic effect by directly affecting the synaptic structures, especially in the hippocampus rather than by simply improving the cerebral blood flow.
Noopept facilitates the processes of initial processing, fixation, and consolidation of information, as well as its extraction. This distinguishes the drug from other means of nootropic series, which can only affect the initial stages of information processing. Noopept increases the resistance of the brain tissue to damaging effects, such as trauma, hypoxia, intoxication, thereby manifesting neuroprotective effects.
The ability of the preparation Noopept to prevent the death of neurons in the culture of the cerebral cortex tissue under the influence of toxic concentrations of glutamate and reactive oxygen species is demonstrated in studies.
Noopept is shown to reduce the toxic effect of beta-amyloid, enhance the production of anti-amyloid antibodies, modulate the work of cholinergic receptors, and stimulate the expression of neurotrophic factors (BDNF and NGF) in the cerebral cortex and hippocampus.
Studies have shown the beneficial effects of the drug in patients with the genotype ApoE 4+, belonging to the group at high risk for the development of Alzheimer’s disease.
Noopept is a promising agent with pro-cognitive properties, which can be used in patients with moderate cognitive impairments of various origins.